ibi110
Showing 1 - 4 of 4
Advanced Malignancies Trial in Shanghai (IBI110, IBI110+ Sintilimab)
Recruiting
- Advanced Malignancies
- IBI110
- IBI110+ Sintilimab
-
Shanghai, ChinaShanghai Pulmonary Hospital
Sep 13, 2022
SCLC Trial in Shanghai (Carboplatin, Cisplatin, Etoposide)
Active, not recruiting
- SCLC
- Carboplatin
- +4 more
-
Shanghai, Shanghai, ChinaShanghai Pulmonary Hospital
Jul 18, 2022
NSCLC (NSCLC) Trial in Tianjin (IBI110, sintilimab)
Recruiting
- Non-small Cell Lung Cancer (NSCLC)
- IBI110
- sintilimab
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Institute and Hospital
Dec 26, 2021
DLBCL Trial in Shanghai (IBI110 plus sintilimab, IBI110)
Not yet recruiting
- DLBCL
- IBI110 plus sintilimab
- IBI110
-
Shanghai, Shanghai, ChinaRuijin Hospital affiliated to Shanghai Jiao Tong University Scho
Sep 1, 2021